Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      Ireland/How we work /Collaborations /Partnering with patient groups

      Partnering with patient groups

      Working with patient advocacy groups (PAGs) deepens our understanding of patients and their needs. This understanding in turn helps us to develop the right medicines and better understanding about our products, so that the medicines we develop are used in the right way.

      Patient organisations play an important role in informing, supporting and assisting patients. As a company, we learn from this interaction, and that helps us in the development of new treatments and in providing useful information.

      The more we can share in the patient journey and learn from each interaction, the better we can serve patients and build solutions.
      It is our goal to ensure that these relationships and partnerships proceed within a principled framework of mutual respect and learning, integrity, independence and transparency.

      Our work with patient advocacy groups (PAGs) fully complies with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice.
      Expand
      This code sets the standards for ensuring that relationships between pharmaceutical companies and PAGs take place in an ethical and transparent manner. The code can be read in full on the IPHA website.

      Johnson & Johnson publishes all transfer of value details to PAGs on its website.

      In accordance with this code, Johnson & Johnson publishes details of all payments, grants and support given to PAGs. We are committed to leveraging our contacts with patient groups. This is to help develop treatment paths that suit patient needs better, without compromising ethical business standards.
      Collapse
      Campaigns
      Ireland has one of the highest mental illness rates in Europe, with around 150,000 people each year living with severe depression [1][2]. Yet many feel isolated and uninformed due to stigma, preventing them from seeking help.[2][3] Talking Depression aims to encourage people to find the right support and to continue conversations about depression.

      On this website, you’ll find expert advice from healthcare professionals, real-life stories from people living with depression, and guidance on treatment options and available supports. Click below to explore the resources available.
      Living with Psoriasis or Psoriatic Arthritis? Hosted by broadcaster Dr Ciara Kelly, PsO Let’s Talk Psoriasis is an award-winning video and podcast series designed to help people manage their condition. This four-part series features healthcare experts and people living with psoriasis, offering advice on treatment options and busting common myths along the way.  
      GutCast is an award-winning podcast series designed for those living with Inflammatory Bowel Disease in Ireland. Each episode brings together healthcare experts and people with IBD to answer the most common questions about managing the condition. From coping with fatigue to balancing work, social life, and mental health, listen to all 17 episodes now.

      References

      1. CSO, Irish Health Survey 2015, see ‘Table 6: All persons aged 15 years and over classified by mental health status in previous two weeks, 2015’. 3% of respondents reporting as experiencing moderately severe or severe depression is estimated MDD patient population. Estimated 150,000 people with MDD is 3% of projected population in 2020 (4.98m). Available at: https://www.cso.ie/en/releasesandpublications/ep/p-ihs/irishhealthsurvey2015/ct/ Accessed: October 2024.
      2. Aware’s national survey reveals high rates of depression and anxiety. Available here: https://www.aware.ie/national-survey-2023/#:~:text=The%20survey%20revealed%20that%20depression,cent)%20stating%20an%20official%20diagnosis Accessed: October 2024.
      3. Patient research on major depressive disorder carried out by Ipsos MRBI between 2nd October – 3rd November 2020 on behalf of Janssen Sciences Ireland.

      CP-485577 l October 2024